======= TUBB4A ======= == Gene Information == * **Official Symbol**: TUBB4A * **Official Name**: tubulin beta 4A class IVa * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=10382|10382]] * **UniProt**: [[https://www.uniprot.org/uniprot/P04350|P04350]] * **Interactions**: [[https://thebiogrid.org/search.php?search=TUBB4A&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TUBB4A|Open PubMed]] * **OMIM**: [[https://omim.org/entry/602662|Open OMIM]] == Function Summary == * **Entrez Summary**: This gene encodes a member of the beta tubulin family. Beta tubulins are one of two core protein families (alpha and beta tubulins) that heterodimerize and assemble to form microtubules. Mutations in this gene cause hypomyelinating leukodystrophy-6 and autosomal dominant torsion dystonia-4. Alternate splicing results in multiple transcript variants encoding different isoforms. A pseudogene of this gene is found on chromosome X. [provided by RefSeq, Jan 2014]. * **UniProt Summary**: Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. |Misat Myo SegII| |Tubulin| |Tubulin C| |internode region of axon| |negative regulation of microtubule polymerization| |myelin sheath| |negative regulation of microtubule polymerization or depolymerization| |regulation of microtubule polymerization| |negative regulation of protein polymerization| |regulation of microtubule polymerization or depolymerization| |ciliary basal body-plasma membrane docking| |structural constituent of cytoskeleton| |axoneme| |G2/M transition of mitotic cell cycle| |negative regulation of protein complex assembly| |negative regulation of supramolecular fiber organization| |cell cycle G2/M phase transition| |negative regulation of cytoskeleton organization| |organelle localization by membrane tethering| |membrane docking| |regulation of microtubule cytoskeleton organization| |regulation of G2/M transition of mitotic cell cycle| |regulation of cell cycle G2/M phase transition| |regulation of microtubule-based process| |regulation of protein polymerization| |mitotic cell cycle phase transition| |cell cycle phase transition| |microtubule| |GTPase activity| |cilium assembly| |regulation of supramolecular fiber organization| |cilium organization| |neuronal cell body| |negative regulation of organelle organization| |GTP binding| |regulation of mitotic cell cycle phase transition| |plasma membrane bounded cell projection assembly| |regulation of cell cycle phase transition| |regulation of protein complex assembly| |cell projection assembly| |microtubule cytoskeleton organization| |regulation of cytoskeleton organization| |organelle localization| |mitotic cell cycle process| |regulation of mitotic cell cycle| |microtubule-based process| |mitotic cell cycle| |negative regulation of cellular component organization| |calcium ion binding| |regulation of cell cycle process| |organelle assembly| |regulation of cellular component biogenesis| |cell cycle process| |cytoskeleton organization| |plasma membrane bounded cell projection organization| |cell projection organization| |regulation of cell cycle| |regulation of organelle organization| |cell cycle| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp190|Vincristine 0.0005μM R04 exp190]]|-1.98| |[[:results:exp451|Atovaquone 15μM R08 exp451]]|-1.9| |[[:results:exp426|FBS-Wisent 0.1 R07 exp426]]|1.7| |[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|1.71| |[[:results:exp332|Adefovir 20μM R07 exp332]]|1.79| |[[:results:exp316|Geldanamycin 0.015 to 0.025μM on day4 R07 exp316]]|1.82| |[[:results:exp144|PFI-3 10μM R03 exp144]]|1.84| |[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|1.84| |[[:results:exp155|UNC1999 2μM R03 exp155]]|1.88| |[[:results:exp319|ABT-702 5μM plus Dimethyloxaloylglycine 11μM R07 exp319]]|2.1| |[[:results:exp273|Cisplatin 0.35μM R06 exp273]]|2.4| |[[:results:exp375|Lenalidomide 20μM R07 exp375]]|2.44| ^Gene^Correlation^ |[[:human genes:h:hgc6.3|HGC6.3]]|0.403| Global Fraction of Cell Lines Where Essential: 0/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 4332 * **Expression level (log2 read counts)**: 4.06 {{:chemogenomics:nalm6 dist.png?nolink |}}